Assessment of drug–drug interaction potential with EDP‐305, a farnesoid X receptor agonist, in healthy subjects
Abstract EDP‐305 is a farnesoid X receptor (FXR) agonist that selectively activates FXR and is a potential treatment for patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. Results from preclinical studies indicate that CYP3A4 is the primary enzyme involved in EDP‐305 metabolism a...
Main Authors: | Alaa Ahmad, Nathalie Adda |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-09-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.13348 |
Similar Items
-
EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects
by: Christine Marotta, et al.
Published: (2023-02-01) -
Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist
by: Derek J. Erstad, et al.
Published: (2018-07-01) -
Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
by: Ludovico Abenavoli, et al.
Published: (2020-06-01) -
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
by: Islam R. Younis, et al.
Published: (2023-03-01) -
Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases
by: Mohammad Almeqdadi, et al.
Published: (2024-01-01)